搜索
 >  其他蛋白>Trastuzumab >TRB-Y7

Anti-Trastuzumab Antibodies

表达区间及表达系统(Source)

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Trastuzumab F(ab')2.

亚型(Isotype)

IgG1/kappa

特异性(Specificity)

Recognizes Trastuzumab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 years under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7) SDS-PAGE gel

Anti-Trastuzumab Antibodies on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Anti-Trastuzumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized trastuzumab at 1 µg/mL, add increasing concentrations of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7, 10% human serum) and then add biotinylated trastuzumab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 19 ng/mL.

Protocol

Biotinylated Human  ELISA

Demonstration of the specificity of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7) to the trastuzumab.

Protocol

Biotinylated Human ELISA

Measured by its neutralizing ability in a functional ELISA. Immobilized trastuzumab at 0.5 μg/mL (100 μL/well) can bind pre-mixed Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7) and Biotinylated Human HER2 (Cat. No. HE2-H82E2) with a inhibition rate of 89%.

Protocol

活性(Bioactivity)-MSD

Biotinylated Human MSD

Anti-Trastuzumab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Trastuzumab at 5 µg/mL, SULFO-Trastuzumab at 5 µg/mL and increasing concentrations of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y7, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 3.9 ng/mL.

Protocol

活性(Bioactivity)-SPR

Biotinylated Human SPR

Anti-Trastuzumab Antibodies (mouse IgG1, Cat. No. TRB-Y7) captured on CM5 chip via anti-mouse antibodies surface, can bind human trastuzumab with an affinity constant of 0.452 nM.

Protocol

 

背景(Background)

Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein.

 

前沿进展

 
货号/价格

TRB-Y7-100ug / ¥3000

TRB-Y7-1mg (500ug X 2) / ¥19800

开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com

消息提示

请输入您的联系方式,再点击提交!

确定